S1354 |
Lansoprazole
|
Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid. |
-
Front Cell Dev Biol, 2021, 9:655559
-
J Virol, 2021, JVI.00190-21
-
Front Microbiol, 2019, 10:2790
|
|
S1389 |
Omeprazole
|
Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome. |
-
Theranostics, 2021, 11(5):2364-2380
-
J Virol, 2021, JVI.00190-21
-
Biosci Rep, 2021, BSR20200842
|
|
S1413 |
Bafilomycin A1 (Baf-A1)
|
Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis. |
-
Nature, 2022, 603(7899):159-165
-
Cell Res, 2022, 32(2):119-138
-
Autophagy, 2022, 1-20
|
|
S1743 |
NEXIUM (esomeprazole magnesium)
|
Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells. |
|
|
S2105 |
Pantoprazole
|
Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
-
J Virol, 2021, JVI.00190-21
-
Front Microbiol, 2019, 10:2790
|
|
S2222 |
PF-3716556
|
PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease. |
|
|
S3666 |
Ilaprazole
|
Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM. |
-
J Virol, 2021, JVI.00190-21
|
|
S4075 |
Zinc Pyrithione
|
Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump. |
-
Cell Chem Biol, 2021, S2451-9456(21)00213-0
-
Biol Reprod, 2019, 100(2):468-478
-
Cell Syst, 2017, 4(6-:600-610
|
|
S4099 |
Dexlansoprazole
|
Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell. |
-
J Virol, 2021, JVI.00190-21
-
Front Microbiol, 2019, 10:2790
|
|
S4212 |
Tenatoprazole
|
Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase. |
-
J Virol, 2021, JVI.00190-21
|
|
S4538 |
Pantoprazole sodium
|
Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
-
J Virol, 2021, JVI.00190-21
|
|
S4665 |
Rabeprazole sodium
|
Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors. |
-
J Virol, 2021, JVI.00190-21
|
|
S4845 |
Rabeprazole
|
Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach. |
-
PLoS Genet, 2022, 18(3):e1010128
-
J Virol, 2021, JVI.00190-21
-
Biochem Pharmacol, 2021, 188:114525
|
|
S5058 |
Revaprazan Hydrochloride
|
Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump. |
-
ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
|
|
S5502 |
Ilaprazole sodium
|
Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation. |
-
J Virol, 2021, JVI.00190-21
|
|
S5608 |
Pantoprazole sodium hydrate
|
Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM. |
-
J Virol, 2021, JVI.00190-21
|
|
S5658 |
Omeprazole Sodium
|
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19. |
-
Theranostics, 2021, 11(5):2364-2380
-
J Virol, 2021, JVI.00190-21
-
Biosci Rep, 2021, BSR20200842
|
|
S1354 |
Lansoprazole
|
Lansoprazole (A-65006, AG-1749) is a proton-pump inhibitor (PPI) that binds covalently to parietal cell H(+),K(+)-ATPase. Lansoprazole prevents the stomach from producing gastric acid. |
- Front Cell Dev Biol, 2021, 9:655559
- J Virol, 2021, JVI.00190-21
- Front Microbiol, 2019, 10:2790
|
|
S1389 |
Omeprazole
|
Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome. |
- Theranostics, 2021, 11(5):2364-2380
- J Virol, 2021, JVI.00190-21
- Biosci Rep, 2021, BSR20200842
|
|
S1413 |
Bafilomycin A1 (Baf-A1)
|
Bafilomycin A1(Baf-A1) is a vacuolar H+-ATPase inhibitor with IC50 of 0.44 nM. Bafilomycin A1 is found to inhibit autophagy while induces apoptosis. |
- Nature, 2022, 603(7899):159-165
- Cell Res, 2022, 32(2):119-138
- Autophagy, 2022, 1-20
|
|
S1743 |
NEXIUM (esomeprazole magnesium)
|
Esomeprazole Magnesium is a proton pump inhibitor to reduce gastric acid secretion through inhibition of H(+)/K(+)-ATPase in gastric parietal cells. |
|
|
S2105 |
Pantoprazole
|
Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
- J Virol, 2021, JVI.00190-21
- Front Microbiol, 2019, 10:2790
|
|
S2222 |
PF-3716556
|
PF 3716556 is a potent and selective P-CAB (potassium-competitive acid blocker), with pIC50 of 6.026 and 7.095 for the inhibition of porcine H+,K+-ATPase activity in ion-leaky and ion-tight assay, respectively, inhibits gastric acid secretion, displays no activity at Na+,K+-ATPase, used for the treatment of gastroesophageal reflux disease. |
|
|
S3666 |
Ilaprazole
|
Ilaprazole (IY-81149) is a new proton pump inhibitor (PPI) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and duodenal ulcer. It inhibits H+/K+-ATPase with an IC50 of 6.0 μM. |
- J Virol, 2021, JVI.00190-21
|
|
S4075 |
Zinc Pyrithione
|
Zinc pyrithione (OM-1563) is an antifungal and antibacterial agent disrupting membrane transport by blocking the proton pump. |
- Cell Chem Biol, 2021, S2451-9456(21)00213-0
- Biol Reprod, 2019, 100(2):468-478
- Cell Syst, 2017, 4(6-:600-610
|
|
S4099 |
Dexlansoprazole
|
Dexlansoprazole (T 168390, TAK 390), the dextrorotatory enantiomer of lansoprazole, is a proton pump inhibitor (PPI) formulated to have dual delayed-release properties. Dexlansoprazole selectively suppresses gastric acid secretion by direct inhibition of the H(+),K(+)-ATPase proton pump in the gastric parietal cell. |
- J Virol, 2021, JVI.00190-21
- Front Microbiol, 2019, 10:2790
|
|
S4212 |
Tenatoprazole
|
Tenatoprazole (TU-199) is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM. Tenatoprazole labels only the gastric H(+),K(+)-ATPase alpha-subunit, approximately 2.6 nM/mg of tenatoprazole is bound to the H(+),K(+)-ATPase. |
- J Virol, 2021, JVI.00190-21
|
|
S4538 |
Pantoprazole sodium
|
Pantoprazole (SKF96022, BY-1023) is a proton pump inhibitor drug that inhibits gastric acid secretion. It works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid. |
- J Virol, 2021, JVI.00190-21
|
|
S4665 |
Rabeprazole sodium
|
Rabeprazole (Aciphex, Dexrabeprazole, Habeprazole) is an antiulcer drug in the class of proton pump inhibitors. |
- J Virol, 2021, JVI.00190-21
|
|
S4845 |
Rabeprazole
|
Rabeprazole is an oral inhibitor of proton pump and blocks the production of acid by the stomach. |
- PLoS Genet, 2022, 18(3):e1010128
- J Virol, 2021, JVI.00190-21
- Biochem Pharmacol, 2021, 188:114525
|
|
S5058 |
Revaprazan Hydrochloride
|
Revaprazan Hydrochloride (YH1885) is a new reversible proton pump inhibitor with long-lasting acid-suppressive effects. Revaprazan Hydrochloride reversibly inhibits H(+)/K(+)-ATPase via binding to the K+-binding site of the pump. |
- ACS Infect Dis, 2021, 10.1021/acsinfecdis.0c00754
|
|
S5502 |
Ilaprazole sodium
|
Ilaprazole (IY-81149) sodium is the sodium salt form of ilaprazole, which is a proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H(+)/K(+)-ATPase in a dose-dependent manner with IC50 of 6 μM in rabbit parietal cell preparation. |
- J Virol, 2021, JVI.00190-21
|
|
S5608 |
Pantoprazole sodium hydrate
|
Pantoprazole (BY10232, SKF96022) sodium hydrate (Protonix) is a potent inhibitor of H+/K(+)-ATPase with IC50 of 6.8 μM. |
- J Virol, 2021, JVI.00190-21
|
|
S5658 |
Omeprazole Sodium
|
Omeprazole Sodium is the sodium salt form of omeprazole, which is a proton pump inhibitor and suppresses gastric acid secretion. Omeprazole Sodium is a metabolism-dependent inhibitor (MDI) of CYP2C19. |
- Theranostics, 2021, 11(5):2364-2380
- J Virol, 2021, JVI.00190-21
- Biosci Rep, 2021, BSR20200842
|
|